Oxurion

Oxurion EPS

The Earnings per Share (EPS) of Oxurion (OXUR.BR) as of Oct 19, 2026 is 0.04 EUR. In the previous year, Earnings per Share (EPS) was -114.82 EUR — a change of -100.03% (higher).

EPS

0.04EUR

YoY

-100.03%

Last updated:

Earnings per Share (EPS) of Oxurion is 2024 0.04 EUR. Earnings per Share (EPS) of Oxurion was 2023 -114.82 EUR. It decreases by -100.03% higher compared to the previous year.

The Oxurion EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2019
-1.31 EUR
Jan 1, 2020
-0.71 EUR
Jan 1, 2021
-7,673.16 EUR
Jan 1, 2022
-3,727.65 EUR
Jan 1, 2023
-114.82 EUR
Jan 1, 2024
0.04 EUR
Jan 1, 2025 (e)
-0.16 EUR
Jan 1, 2026 (e)
-0.03 EUR
The Oxurion EPS history
YEAREPSYoY
est-0.03EUR-81.57%
est-0.16EUR-520.16%
0.04EUR-100.03%
-114.82EUR-96.92%
-3,727.65EUR-51.42%
-7,673.16EUR+1.07 M%
-0.71EUR-45.70%
-1.31EUR+30.74%
-1.01EUR-261.54%
0.62EUR-137.26%
-1.67EUR+59.21%
-1.05EUR-25.85%
-1.42EUR-297.85%
0.72EUR-17.63%
0.87EUR-230.29%
-0.67EUR+41.01%
-0.47EUR-11.14%
-0.53EUR-217.85%
0.45EUR-167.44%
-0.67EUR+46.48%
-0.46EUR+140.48%
-0.19EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oxurion Stock analysis

What does Oxurion do? Oxurion NV is a biotechnology company based in Heverlee, Belgium, operating within the healthcare sector. The company has 77 employees and went public on July 7, 2006. Oxurion focuses on developing and commercializing treatments for vitreoretinal diseases. Its lead product, JETREA (ocriplasmin), received U.S. Food and Drug Administration approval for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. The company collaborates with Alcon, a division of Novartis, for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including cases associated with macular holes of 400 microns or smaller, with launches in the United Kingdom and Germany. Oxurion is also researching anti-PIGF (Placental Growth Factor), known as TB-403, for potential use in ophthalmic and oncology treatments. The company maintains operations in Belgium, the United States, and Ireland, with its headquarters in Heverlee, Vlaams-Brabant. Oxurion's website is www.oxurion.com. Oxurion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oxurion stock

Earnings per Share (EPS) of Oxurion is 0.04 EUR in 2024.

Earnings per Share (EPS) of Oxurion changed from -114.82 EUR to 0.04 EUR, representing a -100.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Oxurion since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Oxurion

All Key Metrics — Oxurion